Immunogenicity and safety of the vaccinia virus LC16m8δ vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol

Vaccine

Volumn 31, Issue 35, 2013, Pages 3549-3557

  Sato, Hirotaka ^a   Jing, Chen ^a   Isshiki, Mao ^a   Matsuo, Kazuhiro ^b   Kidokoro, Minoru ^c   Takamura, Shiki ^d   Zhang, Xianfeng ^a   Ohashi, Takashi ^a   Shida, Hisatoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Kiyose   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CTL; HIV; Recombinant BCG; Recombinant vaccinia; SIV

Indexed keywords

BCG VACCINE; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAG PROTEIN; GAMMA INTERFERON; L SELECTIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; SMALLPOX VACCINE; TETRAMER; UNCLASSIFIED DRUG; VACCINIA VIRUS LC16M8 DELTA VECTOR; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NEUROTOXICITY; NONHUMAN; PATHOGENICITY; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RISK ASSESSMENT; SIMIAN IMMUNODEFICIENCY VIRUS; STAINING; T LYMPHOCYTE; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION;

CTL; HIV; RECOMBINANT BCG; RECOMBINANT VACCINIA; SIV;

AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; BCG VACCINE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CRICETINAE; FEMALE; GENE PRODUCTS, GAG; HIV INFECTIONS; L-SELECTIN; MICE; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; PROMOTER REGIONS, GENETIC; RABBITS; RECEPTORS, CCR7; SMALLPOX VACCINE; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 84880712893     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.071     Document Type: Article

References (35)

1. UNAIDS report on the global AIDS epidemic 2012, http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf [accessed 03.12.12].
2. Cohen M.S., Chen Y.Q., McCauley M., Gamble T., Hosseinipour M.C., Kumarasamy N., et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365(6):493-505.
3. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329(5993):856-861.
4. Huang J., Ofek G., Laub L., Louder M.K., Doria-Rose N.A., Longo N.S. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012, 491(7424):406-412.
5. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326(5950):285-289.
6. Moldt B., Rakasz E.G., Schultz N., Chan-Hui P.Y., Swiderek K., Weisgrau K.L., et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 2012, 109(46):18921-18925.
7. Fukazawa Y., Park H., Cameron M.J., Lefebvre F., Lum R., Coombes N., et al. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 2012, 18(11):1673-1681.
8. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009, 15(3):293-299.
9. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473(7348):523-527.
10. Yasutomi Y., Koenig S., Haun S.S., Stover C.K., Jackson R.K., Conard P., et al. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J Immunol 1993, 150(7):3101-3107.
11. Kawahara M., Matsuo K., Honda M. Intradermal and oral immunization with recombinant Mycobacterium bovis BCG expressing the simian immunodeficiency virus Gag protein induces long-lasting, antigen-specific immune responses in guinea pigs. Clin Immunol 2006, 119(1):67-78.
12. Jensen K., Ranganathan U.D., Van Rompay K.K., Canfield D.R., Khan I., Ravindran R., et al. A recombinant attenuated Mycobacterium tuberculosis vaccine strain is safe in immunosuppressed simian immunodeficiency virus-infected infant macaques. Clin Vaccine Immunol 2012, 19(8):1170-1181.
13. Mphahlele M.J., Mda S. Immunising the HIV-infected child: a view from sub-Saharan Africa. Vaccine 2012, 30(Suppl. 3):C61-C65.
14. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(23):2209-2220.
15. Hashizume S., Yoshizawa H., Morita M., Suzuki K. Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain. Vaccinia viruses as vectors for vaccine antigens 1985, 421-428. Elsevier, Amsterdam. G.V. Ouinnan (Ed.).
16. Kenner J., Cameron F., Empig C., Jobes D.V., Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 2006, 24(47/48):7009-7022.
17. Kennedy J.S., Gurwith M., Dekker C.L., Frey S.E., Edwards K.M., Kenner J., et al. Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis 2011, 204(9):1395-1402.
18. Kidokoro M., Tashiro M., Shida H. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci USA 2005, 102(11):4152-4157.
19. Jin N.Y., Funahashi S., Shida H. Constructions of vaccinia virus A-type inclusion body protein, tandemly repeated mutant 7.5kDa protein, and hemagglutinin gene promoters support high levels of expression. Arch Virol 1994, 138(3/4):315-330.
20. Kidokoro M., Aoki A., Horiuchi K., Shida H. Large-scale preparation of biologically active measles virus haemagglutinin expressed by attenuated vaccinia virus vectors. Microbes Infect 2002, 4(10):1035-1044.
21. Funahashi S., Sato T., Shida H. Cloning and characterization of the gene encoding the major protein of the A-type inclusion body of cowpox virus. J Gen Virol 1988, 69(Pt 1):35-47.
22. Suzuki H., Kidokoro M., Fofana I.B., Ohashi T., Okamura T., Matsuo K. Immunogenicity of newly constructed attenuated vaccinia strain LC16m8Delta that expresses SIV Gag protein. Vaccine 2009, 27(7):966-971.
23. Mackett M., Smith G.L., Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol 1984, 49(3):857-864.
24. Itamura S., Morikawa Y., Shida H., Nerome K., Oya A. Biological and immunological characterization of influenza virus haemagglutinin expressed from the haemagglutinin locus of vaccinia virus. J Gen Virol 1990, 71(Pt 6):1293-1301.
25. Ami Y., Izumi Y., Matsuo K., Someya K., Kanekiyo M., Horibata S., et al. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J Virol 2005, 79(20):12871-12879.
26. Codon Usage Database. Kazusa DNA Research Institute, Japan. [accessed 08.12.12]. http://www.kazusa.or.jp/codon/.
27. Thole J.E., Keulen W.J., De Bruyn J., Kolk A.H., Groothuis D.G., Berwald L.G., et al. Characterization, sequence determination, and immunogenicity of a 64-kilodalton protein of Mycobacterium bovis BCG expressed in escherichia coli K-12. Infect Immun 1987, 55(6):1466-1475.
28. Matsumoto S., Tamaki M., Yukitake H., Matsuo T., Naito M., Teraoka H., et al. A stable Escherichia coli-mycobacteria shuttle vector 'pSO246' in Mycobacterium bovis BCG. FEMS Microbiol Lett 1996, 135(2-3):237-243.
29. Freel S.A., Lamoreaux L., Chattopadhyay P.K., Saunders K., Zarkowsky D., Overman R.G., et al. Phenotypic and functional profile of HIV-inhibitory CD8T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol 2010, 84(10):4998-5006.
30. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004, 22:745-763.
31. Schaeuble K., Hauser M.A., Singer E., Groettrup M., Legler D.F. Cross-talk between TCR and CCR7 signaling sets a temporal threshold for enhanced T lymphocyte migration. J Immunol 2011, 187(11):5645-5652.
32. Sallusto F., Kremmer E., Palermo B., Hoy A., Ponath P., Qin S., et al. Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol 1999, 29(6):2037-2045.
33. Saito T., Fujii T., Kanatani Y., Saijo M., Morikawa S., Yokote H., et al. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA 2009, 301(10):1025-1033.
34. Gordon S.N., Cecchinato V., Andresen V., Heraud J.M., Hryniewicz A., Parks R.W., et al. Smallpox vaccine safety is dependent on T cells and not B cells. J Infect Dis 2011, 203(8):1043-1053.
35. Shida H., Hinuma Y., Hatanaka M., Morita M., Kidokoro M., Suzuki K., et al. Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene. J Virol 1988, 62(12):4474-4480.